EUCTR2004-005094-29-IT进行中（未招募）不适用
A Phase II Study of AP23573, a mTOR Inhibitor, in Female Adult Patients with Recurrent or Persistent Endometrial Cancer
试验速览
- 阶段
- 不适用
- 状态
- 进行中（未招募）
- 入组人数
- 44
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- Female
入选标准
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range
排除标准
- 未提供
研究者
相似试验
进行中（未招募）
1 期
A Phase II Study of AP23573, an mTOR Inhibitor, in Patients with Advanced SarcomaMetastatic and/or unresectable soft tissue or bone sarcoma (excluding GIST).EUCTR2004-002231-92-BEARIAD Pharmaceuticals, Inc.176
已完成
2 期
Study of AP23573 in Patients With Relapsed or Refractory Hematologic Malignancies (8669-024)(COMPLETED)Hematologic MalignanciesMyelodysplastic SyndromesMyeloid MetaplasiaLymphomaLeukemiaNCT00086125Merck Sharp & Dohme LLC57
已完成
2 期
AP23573 in Female Adult Patients With Recurrent or Persistent Endometrial Cancer (8669-019)(COMPLETED)Endometrial CancerNCT00122343Merck Sharp & Dohme LLC45
已完成
2 期
Study of AP23573/MK-8669 (Ridaforolimus), A Mammalian Target of Rapamycin (mTOR) Inhibitor, in Participants With Advanced Sarcoma (MK-8669-018 AM1)(COMPLETED)OsteosarcomaSarcoma, Soft TissueMetastasesLeiomyosarcomaLiposarcomaNCT00093080Merck Sharp & Dohme LLC216
进行中（未招募）
1 期
Phase II study of the mTOR-Inhibitor EVEROLIMUS asmaintenance therapy in patients aged over 60 years with MantleCell Lymphoma (MCL) after first, second, third or fourth linechemotherapyNew title since Protocol Version 4.0Phase II study of the mTOR-Inhibitor EVEROLIMUS asmaintenance therapy in patients aged over 60 years with MantleCell Lymphoma (MCL) after first, second, third or fourth linechemotherapy - CRAD001C2428Strategies to prolong remission duration in elderly patients with MCL are urgently needed. The effects of Rapamycin derivates on MCL cells in vitro and the evolving in vivo data support the further investigation of RAD001 in this incurable diseaseEUCTR2007-005116-12-DETechnical University of Munich